Evidence map›Paper›PMID 28830420›Full record

Trial reportBMC public health2017

A randomised, controlled, two-Centre open-label study in healthy Japanese subjects to evaluate the effect on biomarkers of exposure of switching from a conventional cigarette to a tobacco heating product.

Nathan Gale, Mike McEwan, Alison C Eldridge, Neil Sherwood, Edward Bowen, Simon McDermott, Emma Holmes, Andrew Hedge, Stuart Hossack, Oscar M Camacho and 6 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in BMC public health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 4 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 4 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Nathan GaleBritish American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, UK.
Mike McEwanBritish American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, UK.
Alison C EldridgeBritish American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, UK.
Neil SherwoodNeil Sherwood Consulting, 22 Route de Marnex, CH-1291, Commugny, Switzerland.
Edward BowenEarly Clinical Services Medical Writing, Global Medical and Regulatory Writing, Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds, LS2 9LH, UK.
Simon McDermottEarly Clinical Development, Covance Clinical and Periapproval Services Limited, Ground Floor, Apsley House, 78 Wellington St, Leeds, LS1 2EQ, UK.
Emma HolmesEarly Clinical Development, Covance Clinical and Periapproval Services Limited, Ground Floor, Apsley House, 78 Wellington St, Leeds, LS1 2EQ, UK.
Andrew HedgeEarly Clinical Development, Covance Clinical and Periapproval Services Limited, Ground Floor, Apsley House, 78 Wellington St, Leeds, LS1 2EQ, UK.
Stuart HossackEarly Clinical Development, Covance Clinical and Periapproval Services Limited, Ground Floor, Apsley House, 78 Wellington St, Leeds, LS1 2EQ, UK.
Oscar M CamachoBritish American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, UK.
Graham ErringtonBritish American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, UK.
John McAugheyBritish American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, UK.
James MurphyBritish American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, UK.
Chuan LiuBritish American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, UK.
Christopher J ProctorBritish American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, UK.
Ian M FearonBritish American Tobacco (Investments) Limited, Research and Development, Regents Park Road, Southampton, SO15 8TL, UK. ian_fearon@bat.com.
British American Tobacco (United Kingdom) · GBCovance (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmoking is a leading cause of numerous human disorders including lung cancer, chronic obstructive pulmonary disease, and atherosclerotic cardiovascular disease. The development of modified risk tobacco products (MRTPs) has been suggested as a possible way to reduce the risks of tobacco smoking by reducing exposure to cigarette smoke toxicants. This study is designed to investigate whether biomarkers of such exposure are reduced when smokers switch from smoking commercial cigarettes to using either a novel or a commercially-available tobacco heating product (THP). DESIGN AND

methodsThis study will assess biomarkers of exposure in current smokers who either remain smoking, switch to THP use, or quit all tobacco use completely, for 5 days. The study is an in-clinic (confinement) two-centre, randomised controlled clinical study with a forced-switching design. Subjects of either gender will be aged 23-55 years (minimum legal smoking age plus 3 years), of Japanese origin and with a verified smoking status (assessed by exhaled breath carbon monoxide and urinary cotinine levels). Subjects will have a usual brand cigarette within the International Organisation for Standardisation (ISO) tar band of 6-8 mg and will be judged to be healthy by medical history, physical examination, vital signs, electrocardiography (ECG), clinical biochemistry and lung function tests. The primary objective of this study is to assess changes within groups in selected biomarkers of exposure (BoE) and of biological effect (BoBE) after a forced switch from a commercial control cigarette to either a menthol or a non-menthol THP. Secondary objectives are to assess between-group differences, to determine nicotine pharmacokinetics for cigarettes and THPs, to assess subject's satisfaction with the study products, and to monitor additional endpoints related to safety and product use. DISCUSSION: Data from this study will advance our scientific understanding of the changes in exposure to cigarette smoke toxicants in smokers who switch to using a THP. TRIAL REGISTRATIONS: UMIN000024988 (25th November 2016); ISRCTN14301360 (14th December 2016).

Indexed as

SmokingAdultBiomarkersBreath TestsFemaleHot TemperatureHumansJapanMaleMiddle AgedTobacco ProductsYoung AdultBiomarkersBiomarker of exposureHarm reductionSmokingTobacco heating product

Identifiers

PMID28830420
PMCPMC5567437
OpenAlexW2749880506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.